1.
Wolfgang Lamm, Hannes Kaufmann, Markus Raderer, Martha Hoffmann, Andreas Chott, Christoph Zielinski, Johannes Drach. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 2011;96(7):1008-1014; https://doi.org/10.3324/haematol.2011.041392.